Enzolytics Inc

Company Profile

Enzolytics Inc had its IPO on under the ticker symbol ENZC.

The company operates in the Healthcare sector and Biotechnology industry. Enzolytics Inc has a staff strength of 0 employees.

Stock update

Shares of Enzolytics Inc opened at $0.04 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.04 - $0.04, and closed at $0.04.

This is a -1.48% slip from the previous day's closing price.

A total volume of 2,621,378 shares were traded at the close of the day’s session.

In the last one week, shares of Enzolytics Inc have slipped by -8.26%.

Enzolytics Inc's Key Ratios

Enzolytics Inc has a market cap of $102.42 million, indicating a price to book ratio of 0 and a price to sales ratio of 2083.2595.

In the last 12-months Enzolytics Inc’s revenue was $46590 with a gross profit of $52807 and an EBITDA of $-886773. The EBITDA ratio measures Enzolytics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Enzolytics Inc’s operating margin was -1924.25% while its return on assets stood at -704.71% with a return of equity of 0%.

In Q1, Enzolytics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Enzolytics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-227.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enzolytics Inc’s profitability.

Enzolytics Inc stock is trading at a EV to sales ratio of 1553.3099 and a EV to EBITDA ratio of -11.1243. Its price to sales ratio in the trailing 12-months stood at 2083.2595.

Enzolytics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$5.56 million

Total Liabilities

$4.11 million

Operating Cash Flow

$3.76 million

Capital Expenditure

$0

Dividend Payout Ratio

0%

Enzolytics Inc ended 2024 with $5.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.56 million while shareholder equity stood at $578296.00.

Enzolytics Inc ended 2024 with $0 in deferred long-term liabilities, $4.11 million in other current liabilities, 50825.00 in common stock, $-16024391.00 in retained earnings and $0 in goodwill. Its cash balance stood at $50.00 and cash and short-term investments were $0. The company’s total short-term debt was $1,957,006 while long-term debt stood at $0.

Enzolytics Inc’s total current assets stands at $50.00 while long-term investments were $3.58 million and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.67 million and inventory worth $0.

In 2024, Enzolytics Inc's operating cash flow was $3.76 million while its capital expenditure stood at $0.

Comparatively, Enzolytics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.04

52-Week High

$0.132

52-Week Low

$0.022

Analyst Target Price

$

Enzolytics Inc stock is currently trading at $0.04 per share. It touched a 52-week high of $0.132 and a 52-week low of $0.132. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.04 and 200-day moving average was $0.05 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0.2% are held by institutions.